An observational study in Polypoidal Choroidal Vasculopathy, sponsored by Nihon University. Completed at 1 site in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-01-06.
Sponsored by Nihon University · Observational
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.
55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 5 are open to participants now.
This study's enrollment of 74 is below the median of 121 across 13 observational studies indexed under Polypoidal Choroidal Vasculopathy.
Browse Polypoidal Choroidal Vasculopathy studies →Nihon University is the lead sponsor of 13 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
outpatients in hospital
Exclusion Criteria:
-
Association of Complement Factor H and ARMS2 Genotypes with Response of Polypoidal Choroidal Vasuculopathy to Intravitral Ranibizumab
Time frame: a month after injection
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polypoidal Choroidal Vasculopathy→
Nihon University